New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature

The immunoassays that are available for the serological diagnosis of the more common subtypes of autoimmune blistering diseases such as pemphigus vulgaris (PV) and pemphigus foliaceus (PF) include enzyme-linked immunosorbent assay (ELISA) testing to specific antigens desmoglein (Dsg)1 and Dsg3, dire...

Full description

Bibliographic Details
Main Authors: Rachel R. Xuan, Anes Yang, MD, BMed, MPH, Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, FRCP (Edin)
Format: Article
Language:English
Published: Wolters Kluwer 2018-06-01
Series:International Journal of Women's Dermatology
Online Access:http://www.sciencedirect.com/science/article/pii/S2352647517300813
_version_ 1819289019571240960
author Rachel R. Xuan
Anes Yang, MD, BMed, MPH
Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, FRCP (Edin)
author_facet Rachel R. Xuan
Anes Yang, MD, BMed, MPH
Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, FRCP (Edin)
author_sort Rachel R. Xuan
collection DOAJ
description The immunoassays that are available for the serological diagnosis of the more common subtypes of autoimmune blistering diseases such as pemphigus vulgaris (PV) and pemphigus foliaceus (PF) include enzyme-linked immunosorbent assay (ELISA) testing to specific antigens desmoglein (Dsg)1 and Dsg3, direct immunofluorescence (DIF), indirect immunofluorescence (IIF), and immunoblotting. A review of the literature on the biochip assay was conducted. Six studies investigated the validity of a new biochip, mosaic-based, IIF test in patients with pemphigus and demonstrated its relatively high sensitivity and specificity (Dsg3: 97.62-100%, 99.6-100%; Dsg1: 90%, 100%) in comparison with ELISA (Dsg3: 81-100%, 94-100%; Dsg1: 69-100%, 61.1-100%), and/or IIF (PV: 75-100%, 91.8-100%; PF: 67-100%) using suitable substrates. So far, validation studies of the biochip have been conducted in four countries (Germany, Italy, Turkey, and Poland) but none in the southern hemisphere. Caucasian patients were recruited as normal controls for these studies; thus, the diagnostic value of the biochip remains uncertain in population groups of other ethnicities. A range of disease control patients were recruited including patients with linear immunoglobulin A dermatosis, psoriasis, discoid lupus erythematosus, lichen planus, and noninflammatory skin diseases (e.g., squamous cell carcinoma, basal cell carcinoma, and vascular leg ulcers). Prospective studies with control patients from a diverse range of ethnicities are needed to better validate the biochip.
first_indexed 2024-12-24T03:00:12Z
format Article
id doaj.art-b94ecab54fb24ed89fb8c35e9a53f1dc
institution Directory Open Access Journal
issn 2352-6475
language English
last_indexed 2024-12-24T03:00:12Z
publishDate 2018-06-01
publisher Wolters Kluwer
record_format Article
series International Journal of Women's Dermatology
spelling doaj.art-b94ecab54fb24ed89fb8c35e9a53f1dc2022-12-21T17:18:14ZengWolters KluwerInternational Journal of Women's Dermatology2352-64752018-06-014210210810.1016/j.ijwd.2017.10.001New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literatureRachel R. XuanAnes Yang, MD, BMed, MPHDedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, FRCP (Edin)The immunoassays that are available for the serological diagnosis of the more common subtypes of autoimmune blistering diseases such as pemphigus vulgaris (PV) and pemphigus foliaceus (PF) include enzyme-linked immunosorbent assay (ELISA) testing to specific antigens desmoglein (Dsg)1 and Dsg3, direct immunofluorescence (DIF), indirect immunofluorescence (IIF), and immunoblotting. A review of the literature on the biochip assay was conducted. Six studies investigated the validity of a new biochip, mosaic-based, IIF test in patients with pemphigus and demonstrated its relatively high sensitivity and specificity (Dsg3: 97.62-100%, 99.6-100%; Dsg1: 90%, 100%) in comparison with ELISA (Dsg3: 81-100%, 94-100%; Dsg1: 69-100%, 61.1-100%), and/or IIF (PV: 75-100%, 91.8-100%; PF: 67-100%) using suitable substrates. So far, validation studies of the biochip have been conducted in four countries (Germany, Italy, Turkey, and Poland) but none in the southern hemisphere. Caucasian patients were recruited as normal controls for these studies; thus, the diagnostic value of the biochip remains uncertain in population groups of other ethnicities. A range of disease control patients were recruited including patients with linear immunoglobulin A dermatosis, psoriasis, discoid lupus erythematosus, lichen planus, and noninflammatory skin diseases (e.g., squamous cell carcinoma, basal cell carcinoma, and vascular leg ulcers). Prospective studies with control patients from a diverse range of ethnicities are needed to better validate the biochip.http://www.sciencedirect.com/science/article/pii/S2352647517300813
spellingShingle Rachel R. Xuan
Anes Yang, MD, BMed, MPH
Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, FRCP (Edin)
New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature
International Journal of Women's Dermatology
title New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature
title_full New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature
title_fullStr New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature
title_full_unstemmed New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature
title_short New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature
title_sort new biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus a review of the literature
url http://www.sciencedirect.com/science/article/pii/S2352647517300813
work_keys_str_mv AT rachelrxuan newbiochipimmunofluorescencetestfortheserologicaldiagnosisofpemphigusvulgarisandfoliaceusareviewoftheliterature
AT anesyangmdbmedmph newbiochipimmunofluorescencetestfortheserologicaldiagnosisofpemphigusvulgarisandfoliaceusareviewoftheliterature
AT dedeefmurrellmabmbchfaadmdfacdfrcpedin newbiochipimmunofluorescencetestfortheserologicaldiagnosisofpemphigusvulgarisandfoliaceusareviewoftheliterature